Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Tilray Brands, Inc. TLRY

Alternate Symbol(s):  T.TLRY

Tilray Brands, Inc. is a global cannabis-lifestyle and consumer packaged goods company. The Company operates through four segments: Cannabis business, Distribution business, Beverage alcohol business and Wellness business. The Cannabis business segment is engaged in the production, distribution, sale, co-manufacturing, and advisory services of both medical and adult-use cannabis. The Distribution business segment is focused on the purchase and resale of pharmaceutical products to customers. The Beverage alcohol business segment is engaged in the production, marketing and sale of beverage and beverage alcohol products. The Wellness business segment includes hemp foods and hemp-based cannabidiol (CBD) consumer products. The Company offers a portfolio of adult-use brands and products and expands its portfolio to include new cannabis products and formats. Its brands include Good Supply, RIFF, Broken Coast, Solei, Canaca, HEXO, Redecan, Original Stash, Bake Sale, XMG, Mollo, and others.


NDAQ:TLRY - Post by User

Post by HightideHippieon Mar 09, 2021 12:51pm
185 Views
Post# 32753443

Weed Covid Breakthrough

Weed Covid Breakthrough New York, NY – March 9, 2021 – After facing scrutiny last spring, new research suggests that using cannabis to help treat and prevent COVID-19 isn’t so far-fetched after all. Researchers at the University of Lethbridge are advancing to clinical trials after study results revealed that certain cannabis strains might help prevent COVID-19 patients from experiencing acute respiratory distress (ARDS). At the same time, Michigan State University professor of pharmacology and toxicology Norbert Kaminski is working with GB Sciences, a biopharmaceutical company, to develop a drug that prevents the lung inflammation that some experience after contracting COVID-19 that can lead to trouble breathing and death. The positive test results from these various studies bode well for cannabis companies that have a stake in the edibles and extracts sector, such as industry giants Canopy Growth (NASDAQ:CGC) (TSX:WEED), Tilray, Inc. (NASDAQ:TLRY), Aphria (NASDAQ:APHA) (TSX:APHA), HEXO Corp. (NYSE:HEXO) (TSX:HEXO), and plant-based extraction company Pure Extracts Technologies (CSE:PULL) (OTCPK:PRXTF).
<< Previous
Bullboard Posts
Next >>